These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 8671409)

  • 1. Ovarian hyperstimulation: effects of GnRH analogues. Triggering the final stage of ovulation using gonadotrophin-releasing hormone analogues: effective dose, prevention of ovarian hyperstimulation syndrome and the luteal phase.
    Ben-Arie A; Weissman A; Shoham Z
    Hum Reprod; 1996 Jun; 11(6):1146-8. PubMed ID: 8671409
    [No Abstract]   [Full Text] [Related]  

  • 2. Ovarian hyperstimulation: effects of GnRH analogues. Does triggering ovulation with gonadotrophin-releasing hormone analogue prevent severe ovarian hyperstimulation syndrome?
    Casper RF
    Hum Reprod; 1996 Jun; 11(6):1144-6. PubMed ID: 8671408
    [No Abstract]   [Full Text] [Related]  

  • 3. Ovarian hyperstimulation: effects of GnRH analogues. Ovarian hyperstimulation syndrome after using gonadotrophin-releasing hormone analogue as a trigger of ovulation: causes and implications.
    Kol S; Lewit N; Itskovitz-Eldor J
    Hum Reprod; 1996 Jun; 11(6):1143-4. PubMed ID: 8671407
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
    Krause BT; Ohlinger R
    Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [GnRH agonist triggering in IVF and luteal phase support in women at risk of ovarian hyperstimulation syndrome].
    Guivarc'h-Levêque A; Jaffré F; Homer L; Moy L; Priou G; Colleu D; Denis I; Arvis P
    Gynecol Obstet Fertil; 2013 Sep; 41(9):511-4. PubMed ID: 23972925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of gonadotrophin-releasing hormone analogues and human chorionic gonadotrophin for the induction of ovulation and prevention of ovarian hyperstimulation syndrome: a case-control study.
    Lewit N; Kol S; Manor D; Itskovitz-Eldor J
    Hum Reprod; 1996 Jul; 11(7):1399-402. PubMed ID: 8671474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prevention of ovarian hyperstimulation syndrome.
    Corbett S; Shmorgun D; Claman P; ;
    J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
    Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
    Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GnRH analogue for the prevention of ovarian hyperstimulation syndrome: a pilot study.
    Giles J; Requena A; García-Velasco JA; Pacheco A; Pellicer J; Pellicer A
    Fertil Steril; 2009 Apr; 91(4 Suppl):1366-9. PubMed ID: 18692821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
    Seyhan A; Ata B; Polat M; Son WY; Yarali H; Dahan MH
    Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The luteal phase after GnRH-agonist triggering of ovulation: present and future perspectives.
    Humaidan P; Papanikolaou EG; Kyrou D; Alsbjerg B; Polyzos NP; Devroey P; Fatemi HM
    Reprod Biomed Online; 2012 Feb; 24(2):134-41. PubMed ID: 22197130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Onset and maintenance of the luteal phase with GnRH agonists or hCG in cycles under GnRH antagonists].
    Olivennes F
    J Gynecol Obstet Biol Reprod (Paris); 2004 Oct; 33(6 Pt 2):3S24-6. PubMed ID: 15643682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Medical Strategies in the Prevention of Ovarian Hyperstimulation Syndrome.
    Kasum M; Orešković S; Franulić D; Čehić E; Lila A; Vujić G; Grgić F
    Acta Clin Croat; 2017 Mar; 56(1):133-142. PubMed ID: 29120551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian hyperstimulation following the sole administration of agonistic analogues of gonadotrophin releasing hormone.
    Weissman A; Barash A; Shapiro H; Casper RF
    Hum Reprod; 1998 Dec; 13(12):3421-4. PubMed ID: 9886527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of luteal phase defect and spontaneous pregnancy in IVF patients despite GnRH-agonist trigger and "freeze all policy" without luteal phase support: a report of four cases.
    Gurbuz AS; Deveer R; Ozcimen N; Ozcimen EE; Lawrenz B; Banker M; Garcia-Velasco JA; Fatemi HM
    Gynecol Endocrinol; 2016; 32(1):18-20. PubMed ID: 26487486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.
    Bodri D; Guillén JJ; Galindo A; Mataró D; Pujol A; Coll O
    Fertil Steril; 2009 Feb; 91(2):365-71. PubMed ID: 18367175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GnRH agonist triggering: recent developments.
    Kol S; Humaidan P
    Reprod Biomed Online; 2013 Mar; 26(3):226-30. PubMed ID: 23337420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
    Gerris J; De Vits A; Joostens M; Van Royen E
    Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GnRHa trigger and luteal coasting: a new approach for the ovarian hyperstimulation syndrome high-risk patient?
    Lawrenz B; Humaidan P; Kol S; Fatemi HM
    Reprod Biomed Online; 2018 Jan; 36(1):75-77. PubMed ID: 29102428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovulation induction and luteal support with GnRH agonist in patients at high risk for hyperstimulation syndrome.
    Fusi FM; Arnoldi M; Bosisio C; Lombardo G; Ferrario M; Zanga L; Galimberti A; Capitanio E
    Gynecol Endocrinol; 2015; 31(9):693-7. PubMed ID: 26527503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.